Published: 29 May 2020
Author(s): Alberto Carmona-Bayonas, David Gómez, Eva Martínez de Castro, Pedro Pérez Segura, José Muñoz Langa, Paula Jimenez-Fonseca, Manuel Sánchez Cánovas, Laura Ortega Moran, Ignacio García Escobar, Ana Belén Rupérez Blanco, Isaura Fernández Pérez, Purificación Martínez de Prado, Rut Porta i Balanyà, Teresa Quintanar Verduguez, Álvaro Rodríguez-Lescure, Andrés Muñoz
Issue: August 2020
Section: Original article

Venous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with cancer [1]. Both pathologies interrelate at a deep biological level with numerous interactions between key elements of the hemostatic system and cancer cell programs [2]. Cancer-associated thrombosis (CAT) falls within a panorama of growing complexity in oncology, with the appearance of new anticoagulant therapies, emerging molecular data [3], and new antineoplastic treatments associated with thrombotic risk.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.